Hi-Tech Pharmacal Co., Inc. (NASDAQ NM:HITK), die Sterne stehen auf höhere Kurse - 500 Beiträge pro Seite

[js200]

Hi-Tech Pharmacal Enters into Agreement with Blansett Pharmacal to Promote Naprelan to Physicians

Wednesday, October 06, 2004 16:01 ET

AMITYVILLE, N.Y., Oct 6, 2004 (BUSINESS WIRE) -- Hi-Tech Pharmacal, Co., Inc. (NASDAQ:HITK) announced today that it has entered into an agreement with Blansett Pharmacal Co., Inc. to co-promote Naprelan(R) in the United States. Naprelan(R) extended release tablets is a non-steroidal anti-inflammatory agent was recently licensed by Hi-Tech from Elan Pharmaceuticals, Inc. Blansett based in North Little Rock, AR will promote Naprelan(R) through its sales and marketing force of 130 people directly to primary care physicians across the United States.

Naprelan(R) is a non-steroidal anti-inflammatory agent that has been specially formulated using Elan`s patented IPDAS(TM) (Intestinal Protective Drug Absorption System) technology. Naprelan(R) that is patent protected until 2014, offers the convenience of once-daily dosing and is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing, spondylitis, tendonitis, bursitis, acute gout, primary dysmenorrhea, and mild to moderate pain.

Commenting on the news, David Seltzer, President and CEO of Hi-Tech said, "The arthritis and osteoarthritis pain management market is very big and increasing due to the growing number of elderly people, and the importance of sports medicine. Naprelan(R) is one of the few patented medications in this category and due to its unique release profile offers significant benefits and reduced side effects compared to some of its competitors. We are excited about the opportunity and look forward to work with Blansett to build the awareness of the medical community in the benefits of Naprelan(R). Blansett has over twenty years of marketing and sales experience promoting pharmaceuticals directly to healthcare providers, with a dedicated staff focused on the pain management market."

Larry Blansett, President and CEO of Blansett, said, "We believe that there are significant opportunities for Naprelan(R) at this time created by both the growing number of arthritis sufferers, as well as by widely recognized side effects of Cox-2 inhibitors that currently dominate the market. Naprelan(R) will be promoted as a once-a-day starting dose for rheumatoid arthritis and osteoarthritis. We have an extremely aggressive marketing plan for the product, and plan to launch it in November - December of 2004. The launch will be augmented by a significant expansion of our field force throughout the duration of the agreement."

About Hi-Tech Pharmacal

Hi-Tech is a specialty pharmaceuticals manufacturer and marketer of branded and generic prescription and OTC products for the general health industry. A specialist in liquid and semi-solid dosage form production, Hi-Tech markets a broad line of generic products under its own labels and also serves as a contract manufacturer to the industry. The company`s Health Care Products subsidiary is a leading manufacturer and marketer of branded OTC products for the diabetes marketplace.

About Blansett Pharmacal

Blansett Pharmacal Inc. is a progressive branded specialty pharmaceutical company engaged in the development, commercialization and marketing of prescription pharmaceutical products. Products are promoted directly through the Company`s own expanding sales force nationally and distributed to all 50 states through wholesale drug companies. Major product categories are pain (including tension headache), inflammatory disease, respiratory, women`s health, and otolaryngology. Blansett`s sales team primarily targets Primary Care Physicians, Otolaryngologists, Allergists, Pediatricians, Orthopedics, and the OB-GYN market.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal


CONTACT: Hi-Tech Pharmacal
Bill Peters, 631-789-8228
or
Blansett Pharmacal
Eddy Bowman, 800-816-9695



Copyright (C) 2004 Business Wire. All rights reserved.


-0-


KEYWORD: NEW YORK
INDUSTRY KEYWORD: PHARMACEUTICAL
MEDICAL
RETAIL
MARKETING
AGREEMENTS
Copyright
Business
Wire
2004


STOCK SYMBOLS: [(hitk)]

JS200

[js200]

Last Trade: 15.950 Change: -0.130 (-0.808%)
Previous Close: 16.080 Volume: 26,400
Bid: 15.900 Ask: 16.080
Today`s Open: 15.961 # of Trades: 89

Day High: 16.079 Day Low: 15.850
52 Week High: 75.000 52 week Low: 13.560
Market Cap: 126.91M Avg Daily Vol: 80,281
EPS: 0.73 PE Ratio: 22.000
Dividend: N/A Yield: N/A

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


10/06/2004 (16:13 ET) HITK: Enters Mrkting Agreement w/ Blansett for Naprelan - Knobias



10/06/2004 (16:01 ET) Hi-Tech Pharmacal Enters into Agreement with Blansett Pharmacal to Promote Naprelan to Physicians - Business Wire



10/04/2004 (10:52 ET) HITK: Filed New Form 3 - Edgar



09/29/2004 (16:38 ET) HITK: Filed New Form DEF 14A - Edgar



09/24/2004 (16:17 ET) HITK: Short Interest DN 31.5% to 202.6K in Sep 2004 - Knobias



09/23/2004 (14:14 ET) HITK: Board Elects Puglisi as Director - Knobias



09/23/2004 (14:04 ET) HITK: Filed New Form 8-K - Edgar



09/20/2004 (16:25 ET) HITK: Filed New Form 3 - Edgar



09/15/2004 (15:18 ET) HITK: Filed New Form 4 - Edgar



09/13/2004 (14:32 ET) HITK: To Present At Bear Stearns Health Conference @ 16:15 ET - Knobias



09/10/2004 (12:12 ET) HITK: Seltzer Rejects Re-Election to Board; Elects Simpson - Knobias



09/10/2004 (12:06 ET) HITK: Filed New Form 8-K - Edgar



09/09/2004 (14:20 ET) HITK: Filed New Form 10-Q - Edgar



09/09/2004 (10:41 ET) HITK: Volume Spike; 19% > 20-adsv, Stock +5.68% - Knobias



09/08/2004 (16:53 ET) HITK: Filed 8-K Regarding 1st Qtr Results (Sep-08 PR) - Knobias



09/08/2004 (16:23 ET) HITK: Filed New Form 8-K - Edgar



09/08/2004 (10:11 ET) HITK: Volume Spike; 10% > 20-adsv, Stock +2.71% - Knobias



09/08/2004 (08:12 ET) HITK: Q1 Results 10c vs 11c; Beats 8c Est; In-Line Guidance - Knobias



09/08/2004 (08:02 ET) HITK: Q1 Earnings Call @ 11:00 ET Today - Knobias



09/08/2004 (08:01 ET) Hi-Tech Pharmacal Reports a 31% Sales Increase for the Quarter Ended July 31, 2004 - Business Wire



09/08/2004 (00:12 ET) FirstAlert: 11 A.M. Investrend / Bestcalls - Investrend



09/07/2004 (21:04 ET) MARKETS: After Hours Activity & Late News - Knobias



09/07/2004 (18:01 ET) Hi-Tech Pharmacal to Present at the Bear Stearns 17th Annual Healthcare Conference - Business Wire



09/07/2004 (13:00 ET) HITK: To Release Q1 Results Sep 08 [BMO] - Knobias


JS200

[js200]

HITK: Q1 Results 10c vs 11c; Beats 8c Est; In-Line Guidance

Wednesday, September 08, 2004 08:12 ET

QUARTER RESULTS
Hi-Tech Pharmacal Co., Inc. (HITK) reported Q1 results ended July 2004. Q1 Revenues were $12.14M; +31.10% vs yr-ago; BEATING revenue consensus by +10.36%. Q1 EPS was 10c; -9.09% vs yr-ago; BEATING earnings consensus by +25.00%.

Q1 RESULTS Reported Year-Ago Y/Y Chg Estimate SURPRISE---------- ------------ ------------ ---------- ------------ ----------Revenues: $12.14M $9.26M +31.10% $11.00M +10.36%---------- ------------ ------------ ---------- ------------ ----------EPS: 10c 11c -9.09% 8c +25.00%---------- ------------ ------------ ---------- ------------ ----------
QUARTERLY GUIDANCE:
Company provided NO Revenue guidance for next quarter.

Company provided NO EPS guidance for next quarter.


ANNUAL GUIDANCE:
Company issues Coming-YR Revenue guidance IN-LINE with consensus estimate, expecting:
"Net sales will grow between 15-20% for FY05 or to $64M-$67M"

Company provided NO EPS guidance for coming year.


ADDITIONAL COMMENTARY:
Hi-Tech currently has seven products awaiting approval at the FDA. These products target brand sales of over $300 million. In addition to these products awaiting approval at the FDA, Hi-Tech has twenty products in active development targeting brand sales of over $2.0 billion, including sterile ophthalmic products, oral solutions and suspensions and nasal sprays.

The Companys management reiterates its belief that net sales will grow between 15% and 20% for Fiscal Year 2005.

ORIGINAL EARNINGS RELEASE

Consensus estimate data provided by Multex.com, Inc.
Visit Knobias.com for more indepth earnings information.


JS200

[js200]

http://www.blansett.com/

JS200

[js200]

http://phx.corporate-ir.net/phoenix.zhtml?c=115831&p=IROL-ir…

JS200

[js200]

http://www.hitechpharm.com/

JS200

[js200]

IST die MK gerechtfertigt, bei 50.000.000 Dollar UMSATZ im Jahr, ich sage NEIN !!!!!!!!


Hi-Tech Pharmacal Reports a 31% Sales Increase for the Quarter Ended July 31, 2004
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Sept. 8, 2004--Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter ended July 31, 2004.

Net sales for the three months ended July 31, 2004 were $12,140,000, an increase of $2,876,000 or 31% as compared to the net sales for the three months ended July 31, 2003 of $9,264,000.

Net sales for generic pharmaceutical products, for the three months ended July 31, 2004 were $10,690,000, an increase of $2,286,000, or 27%, compared to the fiscal 2004 respective period sales of $8,404,000. The increase was primarily due to strong sales of Urea 40% Cream and Lotion, the introduction of Ofloxacin Ophthalmic Solution in May and the recent acquisition of Naprelan(R) in June.

JS200

[js200]

50.000.000 Umsatz/ Jahr------------------> MK 127 Mios Mio !!!!!!!!!!!!

JS200

[js200]

Hat sich schon jemand mit der DIABETES-PRODUKT-PALETTE vetraut gemacht von HITK

JS200

[js200]

Na, keine Kommentare ??????

JS200

[bioperformer]

hallo js200,


habe mich mal etwas mit HITK beschäftigt, mein erster Eindruck ist positiver Natur und ich muß zugeben, bis gestern noch nie von diesem Unternehmen gehört zu haben.

Die Umsatzzahlen sind -wie bei den meisten Generikaherstellern - recht gut, werden aber vom Markt nur mit angezogener Handbremse gewürdigt. So erklärt sich auch die in deinen Augen deutlich zu geringe Marktkapitalisierung. Einem das Unternehmen, daß diese Umsätze mit Originalmedikamenten - und nicht wie hier größtenteils mit Generika erzielt, würde mit Sicherheit eine höhere Umsatzmultiple zugestanden werden. Klingt unlogisch, ist aber leider so.
Auch der mit derzeit 8,33 US$ per Share relativ hohe Eigenkapitalanteil ändert daran kaum etwas.

Was allerdings als ziemlicher Hemmschuh für die Investierfreudigen unter uns wirken dürfte, ist zum einen die extreme Marktenge des Titels. 8.080.000 Shares ist schon nicht gerade der wahre Jakob, besonders wenns mal jemand eilig hat mit dem Verkauf...

Was mir zusätzlich noch etwas mißfällt ist das derzeitige Agieren der Institutionellen, die bauen vom zuletzt gehorteten 38%-Anteil nämlich ab.


Zusammenfassend aus meiner Sicht stelle ich das Ding mal in meine Watchlist. Kurzfristig würde ich mich aber nicht für HITK entscheiden. Habe da derzeit etwas anderes im Auge, was ich evtl. mal am Wochenende hier ins Board stellen werde.

Da du offensichtlich ein Freund hoher Umsätze verbunden mit Gewinn und geringer Marktkapitalisierung bist, werden dich bestimmt folgende Eckdaten interessieren:

Klasse Produktpipeline,die Jahresumsatz von knapp 53 Mio.US$ einfährt, dabei erzielter Gewinn 5,8 Mio.US$, was 0,37 US$ per Share entspricht. Eigenkapitalanteil ca. 40 Mio. US$ bei derzeitiger Marktkapitalisierung von rund 86 Mio.US$.

Das waren die Zahlen vom letzten Jahr. Die mir bereits jetzt vorliegenden Zahlen vom 1.Halbjahr 04 sind besser als die Halbjahreszahlen des Vorjahres, das Vorjahresergebnis wird getoppt werden!!!

.....ein geiles Teil

[js200]

@BIOPERFORMER

##### 8.080.000 Shares ist schon nicht gerade der wahre Jakob, besonders wenns mal jemand eilig hat mit dem Verkauf...

Das ist schon richtig, aber wer von uns würde versuchen zbs. 100.000 Teile zu erwerben, niemand

Die Meisten gehen doch nur in diese Teile mit 500----> 2.000 Teile, da sehe ich NULL-Probleme.

######## das derzeitige Agieren der Institutionellen, die bauen vom zuletzt gehorteten 38%-Anteil nämlich ab.

Ein erhöhen des Freefloats könnte auch das Ziel sein, hmmmmm wer weiss.

Erhöhter Freefloat -------- könnte der Aktie guttun........

JS200

[bioperformer]

Hallo js200,


um es gleich vorweg nochmals klarzustellen, ich wollte HITK keinesfalls schlechtreden. Es gibt x-Aktien, die bei weitem nicht so gut aussehen wie diese.

Trotzdem,- und das ist nur meine rein persönliche Meinung- ist der Freeflow sehr gering, die dortige Führungsriege sollte durchaus über "freeflow-bildende" Maßnahmen nachdenken, sonst schon irgendwie der Eindruck entsteht man will unter sich bleiben.

Die Theorie, das Instis zugunsten eines höheren Freefloats eigene Positionen abbauen kannst du getrost vergessen, denn was sollte ein geringprozentiger Abbau von eigenen Shares für besagten Freeflow bringen?

[js200]

@BIOPERFORMER

Wenn man sich die Kurse 2000 und 2001 ansieht , zwischen 4 und 8 Dollar, kann ich mich vorstellen, dass Gewinne realisiert wurden von den INSTIS

Sind immer noch 100---->200%

Ist doch eine schöne Rendite, oder????

Höchst Kurs 50 Dollar ----> 2003

JS200

[js200]

@BIOPERFORMER

########ich wollte HITK keinesfalls schlechtreden

Das hatte ich schon verstanden.

Eine Aktie oder Unternehmen, soll diskutiert werden, und ein Forum ist dazu da seine Meinungen zu äussern.

Viele Anregungen oder Hinweise, können dazu dienen, nicht bekannte Daten zu erforschen und die Überlegungen eines Invest zu überdenken.

MFG

JS200

[js200]

MARKETS: After Hours Activity & Late News

Wednesday, October 06, 2004 21:01 ET

HOTT Sept Sales UP 18% Y/Y; Sept Comps UP 1.1% Y/Y. LTD Sees Q3 EPS 4c-6c, FY EPS $1.30-$1.35; Both IN-LINE. MGPI Guides Lower; Sees Breakeven Qtr vs 19c Est. LAVA Sees Q2 Revenue ABOVE Consensus, Pro Forma EPS IN-LINE. SBUX Sept Sales UP 23%; Comps UP 7%. LZB LOWERS Q2 EPS Guidance; Sees EPS 13c-15c Incl Items. UFAB Announces Majority Owner to Take Co. Private. MGPI Guides Lower; Sees Breakeven Qtr vs 19c Est. MAIR Sept. Traffic Down 1.4% on .1% Increase in Capacity. ISIL Guides Lower; Sees Q3 ADJ EPS Approx. 11c vs 15c Est. UNGL Sees EPS After Tax Impact of (4c)-(5c) on Hurricanes. PXLW Sees Q3 PF EPS 11-12c, GAAP EPS 10-11c vs 10c Estimate. PTIX Sees Q3 EPS 9c-11c, Including Investment vs 7c Est. IUSA Guides Higher; See Q3 Rev of $88-$90M vs $87.3M Est.

- After Hours Advanced

* Homestore Inc (HOMS) - Asset Purchase Agmt w/ Wyld Acq. Corp.
* Spartan Stores, Incorporated (SPTN) - Q2 Results Adj 35c vs 14c; Beats 20c Est; Provides Guidance
* Isis Pharmaceuticals, Inc. (ISIS) - Awarded 3 Govt. Contracts worth Up To $10M
* Hot Topic, Inc. (HOTT) - Sept Sales UP 18% Y/Y; Sept Comps UP 1.1% Y/Y
* Foamex International Inc. (FMXI) - Quality Management System Receives Certification
* Limited Brands Inc (LTD) - Sees Q3 EPS 4c-6c, FY EPS $1.30-$1.35; Both IN-LINE
* Genentech Inc (DNA) - Q3 Results Adj 24c vs 14c; Beats 21c Est; In-Line Guidance

- After Hours Decline

* MGP Ingredients Incorporated (MGPI) - Guides Lower; Sees Breakeven Qtr vs 19c Est.
* Magma Design Automation Inc (LAVA) - Sees Q2 Revenue ABOVE Consensus, Pro Forma EPS IN-LINE
* Starbucks Corporation (SBUX) - Sept Sales UP 23%; Comps UP 7%
* La-Z-Boy Incorporated (LZB) - LOWERS Q2 EPS Guidance; Sees EPS 13c-15c Incl Items

- Late News

* OPNET Technologies, Inc. (OPNT) - Completes Acquisition of Altaworks Corporation
* MGP Ingredients, Inc. (MGPI) - Guides Lower; Sees Breakeven Qtr vs 19c Est.
* UNIFAB International, Inc. (UFAB) - Announces Majority Owner to Take Co. Private
* Verso Technologies, Inc. (VRSO) - Guides Lower; Sees Q3 Rev $11-11.5M vs $19.15M Est.
* MAIR Holdings, Inc. (MAIR) - Sept. Traffic Down 1.4% on .1% Increase in Capacity
* American Campus Communities, Inc. (ACC) - To Be Added to Small-cap Russell 2000
* SYSCO Foodservice (SYY) - Awarded $7M Contract from DEFENSE LOGISTICS
* Lockheed Martin (LMT) - Awarded 2 Military Contract Worth $89.56M
* Jacuzzi Brands, Inc. (JJZ) - Sees Q4 Chrg of $0.08 Per Shr From Plant Closure
* North American Palladium Ltd. (PAL) - Q3 2004 Tons Per Day DOWN From Q2 2004
* Health Care REIT, Inc. (HCN) - Reports Q3 Gross Investments of $297.5M
* Sciax Corp (SCXC) - Signs LOI to Acquire 50% of Nuresco Polymers
* PCTEL, Inc. (PCTI), - Guides Q3 Revenue Lower To $10.9M
* Intersil Corporation (ISIL) - Guides Lower; Sees Q3 ADJ EPS Approx. 11c vs 15c Est
* StarTek, Inc. (SRT) - Completes Sale of Share Capital of StarTek Europe, Ltd
* Veeco Instruments Inc. (VECO) - Completes Acquisition of Manufacturing Technology Inc
* Roper Industries, Inc. (ROP) - To Acquire TransCore Holdings for Approx. $600M
* Isis Pharmaceuticals, Inc. (ISIS) - Awarded 3 Govt. Contract worth Up To $10M
* Pixelworks, Inc. (PXLW) - Sees Q3 PF EPS 11-12c, GAAP EPS 10-11c vs 10c Estimate
* United National Group Ltd (UNGL) - Sees EPS After Tax Impact of (4c)-(5c) on Hurricanes
* The PNC Financial Services Group, Inc. (PNC) - Sees 15c Charge for Q3 Related To BlackRock`s LTIP
* Creo Inc. (CREO) - Reports Restructuring; Sees $6M Charge in Q4
* Delta Air Lines (DAL) - Sept. Traffic Up 8.6% on a 4.6% Increase in Capacity
* Superior Energy Services, Inc. (SPN) - Announces 9.7M Share Public Offering
* Ohana Enterprises, Inc. (OHNA) - Signs Memorandum of Understanding to Acquire CA Bus.
* La-Z-Boy Incorporated (LZB) - LOWERS Q2 EPS Guidance; Sees EPS 13c-15c Incl Items
* PEC Solutions, Inc. (PECS) - Awarded $4.8M Homeland Defense Follow-on Task Order
* BlackRock, Inc. (BLK) - Reaffirms Q3, FY04, & FY05 Guidance After LTIP Charge
* Kansas City Southern (KSU) - Receives Approval to Acquire Interest in TFM, S.A.
* Hi-Tech Pharmacal, Co., Inc. (HITK) - Enters Mrkting Agreement w/ Blansett for Naprelan
* Superior Energy Services Inc (SPN) - Sees Q3 EPS 12c-15c on Hurricane; BELOW 16c Consensus
* Buckeye Partners, L.P. (BPL) - Increases Note Offering to $275M from $250M
* Harris Corporation (HRS) - To Acquire Encoda Systems Holdings, Inc.
* Men`s Wearhouse Inc., The (MW) - Sept Sales UP 7.5%; U.S. Comps UP 1.9%
* American Eagle Outfitters Inc (AEOS) - Sept Sales UP 32.2%; Consolidated Comps UP 22.7%
* Aeropostale, Inc. (ARO) - Sept Sales UP 18.3%; Comps UP 1.9%
* West Marine, Inc. (WMAR) - Reports Sept Net Sales of $54.5M Down 3.7%
* Isonics Corporation (ISON) - Completes $3.3M Round of Private Financing
* Playstar Inc. subsidiary V-Loan (PLYCF) - To Acquire 100% of Confida Group UK
* Homestore, Inc. (HOMS) - Announces Sell of WyldFyre Software Bus for $8.5M Cash
* Honeywell (HON) - To Acquire Certian Intellectual Property from "AZPN"
* Performance Technologies, Inc. (PTIX) - Sees Q3 EPS 9c-11c, Including Investment vs 7c Est
* ATA Holdings Corp. (ATAH) - Sept. Traffic Up 4% on a 8.5% Decrease in Capacity
* infoUSA(R) (IUSA) - Guides Higher; See Q3 Rev of $88-$90M vs $87.3M Est.
* Aspen Technology Inc (AZPN) - Guides Lower; Sees Q1 PF Loss of (2c)-(4c) vs 3c Est

- Late Ratings

* COGN: JMP Sec Keeps @ Strong Buy; Keeps Tgt @ $42; Analyst Notes
* COGN: Moors & Cabot Cuts to Hold from Buy
* SMBI: U.S. Bancorp Starts @ Outperform
* CSE: Fulcrum Starts @ Buy

- Weekly Economic Calendar

* Oct 07 8:30 AM Initial Claims 10/02 - Consensus: NA; Prior: 369K
* Oct 07 3:00 PM Consumer Credit Aug - Consensus: $7.0B; Prior: $10.9B
* Oct 08 8:30 AM Average Workweek Sep - Consensus: 33.7; Prior: 33.8
* Oct 08 8:30 AM Hourly Earnings Sep - Consensus: 0.3%; Prior: 0.3%
* Oct 08 8:30 AM Non-farm Payrolls Sep - Consensus: 153K; Prior: 144K
* Oct 08 8:30 AM Unemployment Rate Sep - Consensus: 5.5%; Prior: 5.4%
* Oct 08 10:00 AM Wholesale Inventories Aug - Consensus: 0.7%; Prior: 1.3%

-Companies Confirmed to Report Before Market Open

Company Name (Symbol); Rev Est.(in Millions); EPS Est.

* ATI Technologies Inc (ATYT); $530.74; 21c
* Costco Wholesale Corp (COST); $15,066.17; 58c
* Centennial Communications Corp. (CYCL); $214.00; 11c
* International Speedway Corporation (ISCA); $151.60; 59c
* Marriott International Inc (MAR); $2,342.77; 55c
* Mercantile Bank Corporation (MBWM); $11.60; 47c
* Matrix Service Company (MTRX); $112.95; 10c
* Q.E.P. Co., Inc. (QEPC); $41.39; 33c


JS200

[Warrant.de]

Ach ja damit wollte ich mich ja heute auch noch beschäftigen!

Kann der Tag nicht 48 Stunden haben?


Mfg
Warrant
(... Zeit ist das einzigste was ich kaum habe! )

[Warrant.de]

ach ja essen sollte ich auch mal was!

Aber ich bin ja nun schon Fett!!! ( Insider)

Mfg
Warrant

[js200]

Last Trade: 16.140 Change: 0.190 (+1.191%)
Previous Close: 15.950 Volume: 51,100
Bid: 15.690 Ask: 16.350
Today`s Open: 15.910 # of Trades: 191

JS200

[js200]

10/08/2004 (16:57 ET) HITK: Filed New Form ARS - Edgar
10/06/2004 (21:01 ET) MARKETS: After Hours Activity & Late News - Knobias
10/06/2004 (16:13 ET) HITK: Enters Mrkting Agreement w/ Blansett for Naprelan - Knobias
10/06/2004 (16:01 ET) Hi-Tech Pharmacal Enters into Agreement with Blansett Pharmacal to Promote Naprelan to Physicians - Business Wire
10/04/2004 (10:52 ET) HITK: Filed New Form 3 - Edgar

JS200

[js200]

Last Trade: 16.590 Change: 0.380 (+2.344%)
Previous Close: 16.210 Volume: 22,400
Bid: 0.010 Ask: 9,000.000
Today`s Open: 16.750 # of Trades: 78

Zieht langsam aber sicher wieder an !!!!!!!!

JS200

[js200]

10/12/2004 (13:20 ET) HITK: Volume Spike; 66% > 20-adsv, Stock +7.03% - Knobias
10/08/2004 (16:57 ET) HITK: Filed New Form ARS - Edgar
10/06/2004 (21:01 ET) MARKETS: After Hours Activity & Late News - Knobias
10/06/2004 (16:13 ET) HITK: Enters Mrkting Agreement w/ Blansett for Naprelan - Knobias
10/06/2004 (16:01 ET) Hi-Tech Pharmacal Enters into Agreement with Blansett Pharmacal to Promote Naprelan to Physicians - Business Wire

[js200]

Last Trade: 16.790 Change: 0.130 (+0.780%)

Langsam aber sicher

JS200

[js200]

10/21/2004 (15:38 ET) HITK: Filed New Form 4 - Edgar
10/21/2004 (14:53 ET) HITK: Filed New Form 4 - Edgar
10/12/2004 (13:20 ET) HITK: Volume Spike; 66% > 20-adsv, Stock +7.03% - Knobias
10/08/2004 (16:57 ET) HITK: Filed New Form ARS - Edgar
10/06/2004 (21:01 ET) MARKETS: After Hours Activity & Late News - Knobias

[js200]

Last Trade: 16.590 Change: -0.150 (-0.896%)
Previous Close: 16.740 Volume: 30,400
Bid: 0.010 Ask: 9,000.000
Today`s Open: 16.620 # of Trades: 64

[js200]

Hi-Tech Pharmacal to Present at the CIBC World Markets 15th Annual Healthcare Conference
via COMTEX

November 2, 2004

AMITYVILLE, N.Y., Nov 2, 2004 (BUSINESS WIRE) --

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the CIBC World Markets 15th Annual Healthcare Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company`s presentation on Wednesday, November 10, 2004, at 11:00 a.m. Eastern Time. The conference is being held November 8 - 10, 2004, at The Plaza Hotel in New York.

A live audio webcast of the Company`s presentation can be accessed at the following address: http://www.veracast.com/webcasts/cibcwm/healthcare04/4430748…

or through the Hi-Tech Pharmacal website: www.hitechpharm.com. A replay will be available at the same link address for up to 30 days after the conference.

About Hi-Tech Pharmacal

Hi-Tech Pharmacal is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc. Bill Peters, 631-789-8228

Copyright (C) 2004 Business Wire. All rights reserved.


JS200

[js200]

Last Trade: 16.990 Change: 0.310 (+1.859%)
Previous Close: 16.680 Volume: 22,300
Bid: 0.010 Ask: 9,000.000
Today`s Open: 16.690 # of Trades: 48

Der Ausbruch scheint zu klappen

JS200

[js200]

HI-TECH PHARMACAL CO INC
Daily Commentary


Our system posted a HOLD today. The previous BUY recommendation that was confirmed was made on 10.19.2004 (18) days ago, when the stock price was 16.3000. Since then HITK has gained 4.23% .

Are you eager to sell your shares? Well we say: “Stick to them for the moment!” Market mood is again bullish. Our SELL-IF alert is not confirmed. It is now null and void and should be ignored.

The current tag is HOLD and it already tells you what to do. Keep holding your stocks until the next signal. Did you already sell without waiting for the confirmation? Do not worry. Chance knocks the door twice. There will be good prices in the next session at which you can buy them back.

[MOTTO OF THE DAY]
When the bulls are in action forget short sale
Stay short or at cash and do not even dare





HOLD


16.990
+0.3100 +1.86%

Candlestick Analysis
Today’s Candlestick Patterns:

White Candlestick




Today a White Candlestick was formed. This represents normal buying pressure.

For more about this candlestick click here.



Stock Quote
Day`s Close 16.990
Previous Close 16.680
Previous Open 16.790
Change +0.3100
% Change +1.86%
Volume 22,310
Stock Activity
Day`s Open 16.690
Day`s High 17.150
Day`s Low 16.640
50-Day Close M.A. 15.948
200-Day Close M.A. 18.503
65-Day Volume M.A. 59,717

[js200]

11/10/2004 (09:02 ET) HITK: To Present At CIBC 15th Healthcare Conference @ 11:00 ET - Knobias
11/02/2004 (16:47 ET) Hi-Tech Pharmacal to Present at the CIBC World Markets 15th Annual Healthcare Conference - Business Wire
11/02/2004 (08:35 ET) SECTOR: M Stanley Sees Near Term Risks in Pharma Group - Knobias
10/29/2004 (13:11 ET) HITK: Volume Spike; 109% > 20-adsv, Stock +0.86% - Knobias
10/26/2004 (16:19 ET) HITK: Short Interest DN 43.0% to 115.5K in Oct 2004 - Knobias

[js200]

11/19/2004 (10:00 ET) StreetInsider Alert for HITK - Street Insider
11/19/2004 (09:54 ET) HITK: Plans to Launch Cough Suppressant After Court Ruling - Knobias
11/19/2004 (09:50 ET) Hi-Tech Pharmacal Announces the Planned Launch of Tannate 12 D S Cough Suspension - Business Wire
11/17/2004 (16:39 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/17/2004 (15:34 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Knobias

[js200]

Hi-Tech Pharmacal Announces the Planned Launch of Tannate 12 D S Cough Suspension

Friday , November 19, 2004 09:50 ET

AMITYVILLE, N.Y., Nov 19, 2004 (BUSINESS WIRE) -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that the U.S. Court of Appeals for the Federal Circuit vacated the preliminary injunction, which had enjoined Hi-Tech from marketing Tannate 12 D S, a generic version of MedPointe`s Tussi-12 D S, a cough suspension. As a result of this decision, Hi-Tech plans to begin shipments of its Tannate 12 D S cough and cold product in the near future. Hi-Tech may still be subject to liability based on a claim of patent infringement for sales of Tannate 12 D S.

David Seltzer, President and CEO, stated that the Company is very pleased with the outcome of this appeal and is preparing to launch this product.

About Hi-Tech Pharmacal

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription and OTC products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded OTC and nutritional products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.


CONTACT: Hi-Tech Pharmacal Co., Inc.
William Peters or David Seltzer
631-789-8228



Copyright (C) 2004 Business Wire. All rights reserved.


-0-


KEYWORD: NEW YORK
INDUSTRY KEYWORD: MEDICAL
DEVICES
PHARMACEUTICAL
MEDICAL
MANUFACTURING
ADVERTISING/MARKETING
Copyright
Business
Wire
2004


STOCK SYMBOLS: [(hitk)]

[js200]

Last Trade: 16.520 Change: 0.180 (+1.102%)
Previous Close: 16.340 Volume: 17,600
Bid: 13.890 Ask: 30.000
Today`s Open: 16.210 # of Trades: 62

11/24/2004 (16:19 ET) HITK: Short Interest UP 14.4% to 132.1K in Nov 2004 - Knobias
11/22/2004 (09:14 ET) SECTOR: Raymond Sees Consolidation in Generic Drug Industry - Knobias
11/19/2004 (10:00 ET) StreetInsider Alert for HITK - Street Insider
11/19/2004 (09:54 ET) HITK: Plans to Launch Cough Suppressant After Court Ruling - Knobias
11/19/2004 (09:50 ET) Hi-Tech Pharmacal Announces the Planned Launch of Tannate 12 D S Cough Suspension - Business Wire

[js200]

Last Trade: 18.090 Change: 0.590 (+3.371%)
Previous Close: 17.500 Volume: 130,600
Bid: 18.080 Ask: 18.130
Today`s Open: 17.510 # of Trades: 217

12/09/2004 (10:02 ET) HITK: Volume Spike; 11% > 20-adsv, Stock +4.29% - Knobias
12/08/2004 (09:51 ET) HITK: Volume Spike; 106% > 20-adsv, Stock +6.51% - Knobias
12/08/2004 (08:20 ET) StreetInsider Alert for HITK - Street Insider
12/08/2004 (08:04 ET) HITK: Q2 Results 27c vs 27c; Beats 16c Est; In-Line Guidance - Knobias
12/08/2004 (08:02 ET) HITK: Q2 Earnings Call @ 11:00 ET Today - Knobias



JS200

[js200]

12/21/2004 (16:05 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Edgar
12/17/2004 (11:30 ET) HITK: Volume Spike; 21% > 20-adsv, Stock +6.07% - Knobias
12/09/2004 (16:57 ET) HITK: Filed New Form 10-Q, Quarterly Report - Knobias
12/09/2004 (10:02 ET) HITK: Volume Spike; 11% > 20-adsv, Stock +4.29% - Knobias
12/08/2004 (09:51 ET) HITK: Volume Spike; 106% > 20-adsv, Stock +6.51% - Knobias

[js200]

Hi-Tech Pharmacal Receives Approval for Ciprofloxacin Ophthalmic Solution
via COMTEX

January 25, 2005

AMITYVILLE, N.Y., Jan 25, 2005 (BUSINESS WIRE) --

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration (FDA) has granted an approval to the Company`s Abbreviated New Drug Application (ANDA) for Ciprofloxacin Ophthalmic Solution USP, 0.3%.

Hi-Tech`s Ciprofloxacin Ophthalmic Solution USP, 0.3% is the generic equivalent of Alcon Laboratories` Ciloxan(R) Ophthalmic Solution, 0.3% indicated for the treatment of bacterial infections. The Company expects to start marketing its Ciprofloxacin Ophthalmic Solution USP, 0.3% in February.

About Hi-Tech Pharmacal

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Statements concerning future results in this release may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and the current economic environment. These statements involve a number of risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. Actual results could differ materially from those expressed or implied in the forward-looking statements and these statements are not guarantees of the future performance.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc. Bill Peters, 631-789-8228 www.hitechpharm.com

Copyright (C) 2005 Business Wire. All rights reserved.

JS200

[js200]

HITK: Volume Spike; 106% > 20-adsv, Stock -3.94%

Friday , February 18, 2005 10:40 ET

This is the 1st VOLUME alert for HITK in the past 7 calendar days.

Trading for Hi-Tech Pharmacal Co., Inc. (NASDAQ NM: HITK) has been heavier than usual in today`s session. By 10:40 ET, the stock had already traded 40,700 shares via 41 trades. The cumulative volume is 105.94% above its 20-day average of 19,763. Normally the stock experiences around 50 individual trades per session.

So far, today`s volume surge has caused a net decline in HITK`s stock price. At the time of this alert, the stock was trading at $16.830, down $-0.690 (-3.94%).

One year ago, the Company`s shares closed at $24.070. The price has declined more than 30 percent since then.

Over the last 10 trading session HITK has traded in a range between $17.500 and $18.680 and is currently trading 36.49% below its 52-week high of $26.500 set on March 05,2004 and 24.12% above its 52-week low of $13.560 from August 16,2004.

In the previous 3 sessions, HITK trading has displayed a mixed trend. Closing results have been as follows:

February 17, 2005 --- closed at $17.520 down $0.180 (-1.02%) on 35,190 shares
February 16, 2005 --- closed at $17.700 down $0.210 (-1.17%) on 19,430 shares
February 15, 2005 --- closed at $17.910 up $0.050 (+0.28%) on 15,370 shares

The Company last released news on January 25, 2005:

"Hi-Tech Pharmacal Receives Approval for Ciprofloxacin Ophthalmic Solution"

HI-TECH PHARMACAL CO., INC.
Growing specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develop, manufacture and market generic and branded products.

[js200]

Hi-Tech Pharmacal Reports a 17% Sales Increase and a 58% EPS Increase for Its Third Fiscal Quarter Ended January 31, 2005
via COMTEX

March 10, 2005

AMITYVILLE, N.Y., Mar 10, 2005 (BUSINESS WIRE) --

Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the quarter and nine months ended January 31, 2005.

Third Quarter Results

For the three months ended January 31, 2005, the Company reported net sales of $21.2 million, an increase of 17% from $18.0 million for the same period last year. Net income increased 50% to $3.2 million from $2.1 million and fully diluted earnings per share rose 58% to $0.38 compared to $0.24 for the same fiscal quarter last year. The change in net income was primarily the result of increased sales and improved gross margin. During the quarter ended January 31, 2005, net sales of generic pharmaceutical products were $18.6 million, an increase of 20% compared to $15.5 million for the same fiscal 2004 period. The increase was driven by the launch of four new products this quarter, including Tannate 12 D S, a generic version of Tussi(R) 12 D S.

Sales for the Health Care Products division, which markets the Company`s branded products, increased 2% to $2.6 million for the three months ended January 31, 2005 due to sales increases of the DiabetiDerm(R) line of products.

Nine Month Results

For the nine months ended January 31, 2005, the Company reported net sales of $50.0 million, an increase of 17% from net sales of $43.0 million for the nine months ended January 31, 2004. Net income increased 16% to $6.4 million or $0.74 per fully diluted share for the nine months ended January 31, 2005 compared to $5.5 million, or $0.62 per share, for the same period ended January 31, 2004. The net income increase was driven by higher sales. The increase was partially offset by a research and development expense increase of 55% to $3.7 million, or 7% of net sales, for the nine months ended January 31, 2005, from $2.4 million, or 6% of net sales for the nine months ended January 31, 2004.

Generic pharmaceutical product sales were $43.4 million for the nine month period ended January 31, 2005, compared to $37.8 million for the nine months ended January 31, 2004 respectively, an increase of 15%. The Health Care Products division had net sales of $6.6 million and $5.2 million for the nine months ended January 31, 2005 and 2004, respectively, an increase of approximately 30%.

David Seltzer, President and CEO, commented on the results: "We are very pleased with the record results reported for our third quarter. Hi-Tech received an FDA approval to market Ciprofloxacin ophthalmic solution and successfully launched four new products this quarter. One of the products, Tannate 12 D S, a generic version of Tussi(R) 12 D S remains the subject of patent litigation. The sales of our Health Care Products division have grown 30% driven by the solid performance of our sugar free Diabetic Tussin(R) cough and cold line, complemented by strong growth from our DiabetiDerm(R) line. We will stay focused on delivering on our new product development plan that we believe will lead to new product introductions in the future."

Hi-Tech currently has nine products awaiting approval at the FDA. These products target brand sales of over $1 billion. In addition to these products awaiting approval at the FDA, Hi-Tech has fifteen products in active development targeting brand sales of over $1 billion, including sterile ophthalmic products, oral solutions and suspensions and nasal sprays.

The Company`s management reiterates its belief that net sales will grow between 15% and 20% for Fiscal Year 2005. The Company`s ability to meet the forecast depends on such factors as the timing of new product launches, regulatory approvals, competition, legal proceedings and other market conditions.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription and OTC products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, the outcome of the SEC staff`s investigation and any conclusions reached by the staff which are adverse to the Company, its officers or directors, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


JS200

[js200]

03/15/2005 (10:40 ET) HITK: Filed 8-K Regarding 3rd Qtr Results (Mar-10 PR) - Knobias
03/15/2005 (10:38 ET) HITK: Filed New Form 8-K, Material Event Disclosure - Edgar
03/14/2005 (15:14 ET) HITK: Filed New Form 10-Q, Quarterly Report - Edgar
03/11/2005 (10:10 ET) HITK: Volume Spike; 13% > 20-adsv, Stock +5.30% - Knobias
03/10/2005 (16:17 ET) MARKET: Indices Close Mixed; NSM Beats Estimates - Knobias

[js200]

HITK: Short Interest DN 17.7% to 141.7K in Mar 2005

Thursday , March 24, 2005 16:18 ET

According to new short interest data from NASDAQ, short interest for Hi-Tech Pharmacal Co., Inc. (NasdaqNM: HITK) DECREASED 17.7% to 141,672 shares for the month ended mid-March, 2005.

SYMBOL FEBRUARY MARCH CHANGE %CHANGE DAYS/COVER
-------- ------------- ------------- ------------- ------------ ----------
HITK 172,242 141,672 -30,570 -17.75% 2
Based on HITK`s 20-day average daily share volume of 81,369, it would require approximately 2 day(s) of buying to cover this short interest.

[js200]

Hi-Tech Pharmacal Receives Tentative Approval for Levofloxacin Ophthalmic Solution
via COMTEX

March 30, 2005

AMITYVILLE, N.Y., Mar 30, 2005 (BUSINESS WIRE) --

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration (FDA) has granted tentative approval to the Company`s Abbreviated New Drug Application (ANDA) for Levofloxacin Ophthalmic Solution USP, 0.5%. Hi-Tech`s Levofloxacin Ophthalmic Solution USP, 0.5% is the generic equivalent of Santen`s Quixin(R) Ophthalmic Solution, 0.5% indicated for the treatment of bacterial infections.

The Company filed the ANDA under Paragraph IV Certification and believes it was first to file the ANDA for the ophthalmic product. Daiichi Pharmaceutical filed a complaint against the Company in December 2003 alleging infringement of its patent which is sublicensed to Santen, seeking a permanent injunction. The Company filed an answer and counterclaim in February 2004 denying such infringement. Fact discovery is completed and no trial date has been set. The Company expects to start marketing the product pending the favorable outcome of all relevant patent litigation.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, the outcome of the SEC staff`s investigation and any conclusions reached by the staff which are adverse to the Company, its officers or directors, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc. Bill Peters, 631-789-8228 www.hitechpharm.com

Copyright Business Wire 2005

[js200]

Bell2Bell.com: Thursdays Stocks of Interest: STTC, VIVI, HITK
via COMTEX

March 31, 2005

SARASOTA, Fla., Mar 31, 2005 (M2 PRESSWIRE via COMTEX) --

SoftNet Technology (OTCBB: STTC), Viva International, Inc. (OTCBB: VIVI), Hi-Tech Pharmacal Co. Inc. (Nasdaq: HITK)

Investors may want to have a look at SoftNet Technology (OTCBB: STTC). On Wednesday the company announced that it has and will generate more revenue than ever recorded in a 30 day period for the month of March. Additionally, the Company said it will record more revenue in the first quarter than ever recorded in any one Quarter before.

SoftNet Technology said that two of its wholly owned subsidiaries, Indigo Technology and WholesaleByUs, have ramped up their operations in the past 90 days to accelerate revenues at a quickened pace. The company said that each of the subsidiaries will generate their best performance for one quarter (this first quarter), in their respective histories, and added that, more impressively, Indigo and WBU each will have generated more than 50% of their total revenues for the quarter in just the month of March. SoftNet Technology as a company said it is expecting to generate approximately $200,000 in sales for just the month of March, the best one month in the company`s history. STTC added that its wholly owned subsidiary, (WBU) www.wbushopping.com, individually will generate record revenues for the month of March, with total Internet sales for the month far exceeding $150,000. The company said that more than two thirds of the revenues in March were generated, astonishingly, in the second half of the month, made possible from all of the technology and procedure changes that were made in December 2004 and January 2005.

In other Company news, STTC announced that its subsidiary, Solutions Technology, has hired sales people in an initial effort to begin a large scale rollout of the SecureTime System. The company said that final programming adjustments are being made as well for SoftNet International GmbH in preparation of turning the WBU System live in foreign countries with products for sale from those foreign jurisdictions. The company noted the Media Blitz with TVA productions has begun and will ramp up and be in full swing over the next 30 days.

Shares of STTC closed Wednesday`s trading session at $0.215.

Other stocks showing interesting activity on Wednesday were;

Viva International, Inc. (OTCBB: VIVI)

Viva International, Inc. announced Wednesday that its wholly owned subsidiary, Eastern Caribbean Air Corporation (EC AIR), has received DOT approval to operate. The company said the approval from the DOT allows EC AIR to begin operations immediately as Cool Tours, Inc. d/b/a Eastern Caribbean Air using its trade name EC AIR.

Shares of VIVI closed Wednesday`s trading session at $0.25, up 5 cents, on volume of 1.85 million shares.

Hi-Tech Pharmacal Co. Inc. (Nasdaq: HITK)

Specialty pharmaceutical company, Hi-Tech Pharmacal Co. Inc., announced after the closing bell Wednesday that the US Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application for Levofloxacin Ophthalmic Solution 0.5%. The company said that Levofloxacin Ophthalmic Solution 0.5% is the generic equivalent of Santen`s Quixin Ophthalmic Solution 0.5% indicated for the treatment of bacterial infections.

Shares of HITK closed Wednesday`s regular trading session at $22.40 on above average volume.

About eLocity Inc: eLocity owns and operates three financial websites for investors.

-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.

-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.

-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company received compensation for newsletter and ad services for STTC. (Public Company). The compensation is three thousand six hundred dollars from a non-affiliated third party Equity Alliance. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

CONTACT: eLocity Inc Tel: [phone]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD

[js200]

Hi-Tech Pharmacal to Present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference
via COMTEX

March 31, 2005

AMITYVILLE, N.Y., Mar 31, 2005 (BUSINESS WIRE) --

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company`s presentation on Tuesday, April 5, 2005, at 8:30 a.m. Eastern Time. The conference is being held at The Millennium Broadway in New York City on April 4th and April 5th.

A live audio webcast of the Company`s presentation can be accessed at the following address: http://www.veracast.com/webcasts/cibcwm/biotech05/15215334.c… or through the Hi-Tech Pharmacal website: www.hitechpharm.com. A replay will be available at the same link address for 30 days after the conference.

About Hi-Tech Pharmacal

Hi-Tech Pharmacal is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, the outcome of the SEC staff`s investigation and any conclusions reached by the staff which are adverse to the Company, its officers or directors, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc. Bill Peters, 631-789-8228

Copyright Business Wire 2005

[js200]

Hi-Tech Pharmacal Launches Authorized Generic of BioMarin Pharmaceutical`s Orapred
via COMTEX

April 4, 2005

AMITYVILLE, N.Y., Apr 04, 2005 (BUSINESS WIRE) --

Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today announced that it entered into a Licensing and Supply Agreement with BioMarin with regard to a generic version of BioMarin`s Orapred(R) oral solution. Pursuant to the terms of this agreement, BioMarin will manufacture a private label version of its Orapred(R) oral solution (prednisolone sodium phosphate EQ 15 mg base/5 ml oral solution) and Hi-Tech will sell and market that version. Hi-Tech will pay BioMarin a transfer price based on the cost of producing the private label product and will also pay an additional amount based on the net sales of the private label product. Hi-Tech launched the product under its label in March, 2005.

About Hi-Tech Pharmacal

Hi-Tech Pharmacal is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, the outcome of the SEC staff`s investigation and any conclusions reached by the staff which are adverse to the Company, its officers or directors, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc. Bill Peters, 631-789-8228

Copyright Business Wire 2005

[js200]

09/15/2005 (12:46 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Edgar
09/13/2005 (14:02 ET) HITK: To Present At Bear Stearns Conference @ 16:00 ET - Knobias
09/09/2005 (11:52 ET) HITK: Filed New Form 10-Q, Quarterly Report - Edgar
09/08/2005 (16:25 ET) Stocks Weaken Late; Semis Sector Near 52-Wk High; MOT Hits 52-Wk High - Knobias
09/08/2005 (10:40 ET) HITK: Volume Spike; 12% > 20-adsv, Stock +6.58% - Knobias

[js200]

10/03/2005 (12:42 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Edgar
09/30/2005 (16:08 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Edgar
09/30/2005 (13:23 ET) HITK: Filed New Form ARS, Annual Report to Security Holders - Edgar
09/28/2005 (17:15 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Edgar
09/27/2005 (17:28 ET) HITK: New Form 4 Filed, Change in Beneficial Ownership - Edgar

[js200]

Last Trade: 31.250 Change: 1.040 (+3.443%)
Previous Close: 30.210 Volume: 82,000
Bid: 0.010 Ask: 9,000.000
Today`s Open: 30.700 # of Trades: 211

[js200]

Last Trade: 32.700 Change: 0.520 (+1.616%)
Previous Close: 32.180 Volume: 58,300
Bid: 32.600 Ask: 32.670
Today`s Open: 32.600 # of Trades: 162

[js200]

11/21/2005 (09:52 ET) HITK: New 52-Wk High @ $41.250 up 0.73% - Knobias
11/21/2005 (09:08 ET) Bird Flu Names Mostly Higher in Pre-Mkt - Knobias
11/17/2005 (09:46 ET) HITK: New 52-Wk High @ $40.500 up 0.82% - Knobias
11/16/2005 (13:55 ET) HITK: New 52-Wk High @ $39.980 up 3.39% - Knobias
11/14/2005 (08:00 ET) Hi-Tech Pharmacal Added to the NASDAQ Biotechnology Index - Business Wire

[js200]

Last Trade: 42.100 Change: 1.150 (+2.808%)
Previous Close: 40.950 Volume: 151,700
Bid: 41.350 Ask: 42.750
Today`s Open: 41.200 # of Trades: 279

[js200]

Hi-Tech Pharmacal Added to the NASDAQ Biotechnology Index

Monday , November 14, 2005 08:00 ET

AMITYVILLE, N.Y., Nov 14, 2005 (BUSINESS WIRE) -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK), a specialty pharmaceuticals company, announced today that the Company has been selected to be included in the NASDAQ Biotechnology Index(R) (NASDAQ: NBI) effective with the market open on Monday, November 21, 2005.

The securities in the Index must be listed on the NASDAQ National Market and be classified according to the FTSE(TM) Global Classification System as either biotechnology or pharmaceutical. Additionally, securities in the Index must meet minimum requirements for market value, average daily share volume and seasoning as a public company among other criteria.

David Seltzer, President and CEO, commented, "We are pleased to join other growth companies in our sector, and believe that our addition to the Index testifies to the Company`s consistent performance."

About Hi-Tech Pharmacal

Hi-Tech Pharmacal is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company`s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, the outcome of the SEC staff`s investigation and any conclusions reached by the staff which are adverse to the Company, its officers or directors, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission. These statements are based on management`s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal
Bill Peters, 631-789-8228

Copyright Business Wire 2005

**********************************************************************

As of Thursday, 11-10-2005 23:59, the latest Comtex SmarTrend(SM) Alert,
an automated pattern recognition system, indicated an UPTREND on
09-08-2005 for HITK @ $28.40.

(C) 2005 Comtex News Network, Inc. All rights reserved.

[js200]

2004



Last Trade: 15.950 Change: -0.130 (-0.808%)
Previous Close: 16.080 Volume: 26,400
Bid: 15.900 Ask: 16.080
Today`s Open: 15.961 # of Trades: 89



2005

Last Trade: 42.100 Change: 1.150 (+2.808%)
Previous Close: 40.950 Volume: 151,700
Bid: 41.350 Ask: 42.750
Today`s Open: 41.200 # of Trades: 279

Na, wer war mit dabei ????????

JS200